在布伦伯格研究所的实验室中进行的其他项目

StephenW

Additional projects being undertaken in Blumberg Institute labs:
Novel STING Agonists: A Potential Cure for HBV and Liver Cancer
Blumberg scientists have discovered new STING agonists that are highly effective in turning on
an immune response against HBV and cancers. Activation of STING with small molecular
agonists not only induces the production of antiviral cytokines that restrict viral replication,
but also activates a powerful adaptive immune response that can clear the virus-infected cells
and cure chronic viral infections, such as HBV. They have also found that intra-tumor delivery
of STING agonists can induce the programmed cancer cell death and activate anti-cancer
immunity for sustained control of tumor growth. With increased financial support, They will
further optimize our lead STING agonists and refine our liver-targeted delivery vehicle to
develop the STING agonists as a potential drug to cure HBV and liver cancers.
New Drug Targets HBsAg: To Improve Recognition of HBV by the Immune System
Researchers at the Blumberg Institute have discovered a concept-proving drug (252-C4-MPI)
that suppresses HBV production and appears to change its antigenic ‘face’ (HBsAg) with the
expectation that it will cause virus recognition by the immune system. An important new
strategy is to find a drug that can selectively modify the HBV proteins (or antigens) such that
the virus becomes recognized and can then be eliminated by the immune system. With
increased funding, they can pursue preclinical models for determining if our drug has the
ability to alter the HBV’s protein (antigen) structure so that it is safely recognized and attacked
by the immune system. If it does, they will know the approach is possible and can further
develop this drug or identify other drugs that work similarly through our screening process.
These would then become ‘first in class’ HBV drugs.
New Platform Technology: For the Early Detection of Liver Cancer
Blumberg scientists have detected a specific “mRNA” in the blood that could be used as a new
early detection marker of liver cancer. The mRNA we detected is associated with cancer
proteins that are not normally in the blood and could, therefore, become part of a simple
blood test. People living with chronic HBV are at significant risk for dying prematurely from
liver cancer. Early detection is critical to survival, but current screening methods for liver
cancer are expensive, inaccurate, or unreliable.

StephenW

在布伦伯格研究所的实验室中进行的其他项目：
新型STING激动剂：HBV和肝癌的潜在治疗方法
Blumberg科学家发现了新的STING激动剂，它们在开启时非常有效
针对HBV和癌症的免疫反应。用小分子激活STING
激动剂不仅会诱导产生限制病毒复制的抗病毒细胞因子，
而且还能激活强大的适应性免疫反应，从而清除感染了病毒的细胞
并治愈HBV等慢性病毒感染。他们还发现肿瘤内分娩
STING激动剂可以诱导程序性癌细胞死亡并激活抗癌
持续控制肿瘤生长的免疫力。随着财政支持的增加，他们将
进一步优化我们的主要STING激动剂，并优化我们的肝脏靶向给药载体，
开发STING激动剂作为治疗HBV和肝癌的潜在药物。
新药靶向HBsAg：提高免疫系统对HBV的识别
Blumberg研究所的研究人员发现了一种概念验证药（252-C4-MPI）
会抑制HBV的产生，并通过改变其抗原性“面部”（HBsAg）
期望它将引起免疫系统识别病毒。一个重要的新
策略是寻找一种可以选择性修饰HBV蛋白（或抗原）的药物，
病毒被识别，然后可以被免疫系统清除。用
增加资金，他们可以采用临床前模型来确定我们的药物是否具有
能够改变HBV的蛋白质（抗原）结构，从而使其被安全地识别和攻击
通过免疫系统。如果可以，他们将知道该方法是可行的，并且可以进一步
开发这种药物或确定在我们的筛选过程中具有相似作用的其他药物。
这些将成为“一流”的HBV药物。
新平台技术：用于早期发现肝癌
Blumberg科学家已经在血液中检测到一种特定的“ mRNA”，可以用作新的
肝癌的早期发现标志物。我们检测到的mRNA与癌症有关
血液中通常不存在的蛋白质，因此可能成为简单疾病的一部分
验血。患有慢性HBV的人有过早死亡的危险。
肝癌。早期发现对生存至关重要，但是目前的肝筛查方法
癌症昂贵，不准确或不可靠。